Stevanato Group Past Earnings Performance
Past criteria checks 1/6
Stevanato Group has been growing earnings at an average annual rate of 11.6%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 13.5% per year. Stevanato Group's return on equity is 8.7%, and it has net margins of 10.5%.
Key information
11.6%
Earnings growth rate
9.2%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 13.5% |
| Return on equity | 8.7% |
| Net Margin | 10.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Stevanato Group S.p.A. (NYSE:STVN) Not Lagging Market On Growth Or Pricing
Dec 09
Stevanato: Supportive Biopharmaceutical And Diagnostic Segment And Destocking Improvement
Nov 13Stevanato Group's (NYSE:STVN) Anemic Earnings Might Be Worse Than You Think
Nov 12Stevanato Group S.p.A. Just Missed Earnings - But Analysts Have Updated Their Models
Nov 08We Think Stevanato Group (NYSE:STVN) Is Taking Some Risk With Its Debt
Oct 23Is Stevanato Group S.p.A. (NYSE:STVN) Worth US$19.3 Based On Its Intrinsic Value?
Aug 21Stevanato Group S.p.A. (NYSE:STVN) Looks Just Right With A 28% Price Jump
Jul 25Does Stevanato Group (NYSE:STVN) Have A Healthy Balance Sheet?
Jul 23Stevanato: Destock Pressures, Long-Term Upside
May 29Stevanato Group S.p.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 12Stevanato Group S.p.A.'s (NYSE:STVN) Share Price Matching Investor Opinion
May 07Stevanato Group's (NYSE:STVN) Solid Earnings May Rest On Weak Foundations
Mar 15Stevanato: Destocking And Valuation Risk (Rating Downgrade)
Mar 12Is Stevanato Group S.p.A. (NYSE:STVN) Expensive For A Reason? A Look At Its Intrinsic Value
Feb 09Stevanato: Guidance Reiterated And Supportive Revenue Growth
Nov 22Stevanato: Secular Tailwinds In Biologics Support Downstream Demand
Sep 15Stevanato Group: Undeniable Quality, But Lacking Upside
Jun 14Stevanato Group and Transcoject to provide pre-fillable syringe polymer options for pharma
Jan 24Stevanato Group Non-GAAP EPS of $0.14 beats by $0.01, revenue of $245.3M in-line
Nov 08Revenue & Expenses Breakdown
How Stevanato Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,094 | 115 | 116 | 35 |
| 30 Jun 24 | 1,088 | 123 | 113 | 38 |
| 31 Mar 24 | 1,083 | 136 | 113 | 37 |
| 31 Dec 23 | 1,085 | 146 | 114 | 36 |
| 30 Sep 23 | 1,057 | 149 | 117 | 36 |
| 30 Jun 23 | 1,031 | 147 | 117 | 35 |
| 31 Mar 23 | 1,010 | 143 | 117 | 35 |
| 31 Dec 22 | 984 | 143 | 112 | 34 |
| 30 Sep 22 | 924 | 139 | 100 | 33 |
| 30 Jun 22 | 893 | 122 | 95 | 33 |
| 31 Mar 22 | 863 | 125 | 86 | 31 |
| 31 Dec 21 | 844 | 134 | 83 | 30 |
| 30 Sep 21 | 818 | 123 | 82 | 25 |
| 30 Jun 21 | 761 | 121 | 79 | 22 |
| 31 Mar 21 | 718 | 108 | 79 | 19 |
| 31 Dec 20 | 662 | 79 | 79 | 17 |
| 31 Dec 19 | 537 | 39 | 77 | 8 |
Quality Earnings: STVN has a high level of non-cash earnings.
Growing Profit Margin: STVN's current net profit margins (10.5%) are lower than last year (14.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STVN's earnings have grown by 11.6% per year over the past 5 years.
Accelerating Growth: STVN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: STVN had negative earnings growth (-22.9%) over the past year, making it difficult to compare to the Life Sciences industry average (-4.7%).
Return on Equity
High ROE: STVN's Return on Equity (8.7%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:45 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Stevanato Group S.p.A. is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Curtis Moiles | BNP Paribas Exane |
| Derik de Bruin | BofA Global Research |